^
    Back
    Association details:
    Biomarker:IDH2 mutation
    Cancer:Glioma
    Drug:zotiraciclib (TG02) (CDK9 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

    Excerpt:
    ...- IDH1 or IDH2 mutation status confirmed by TSO500 performed in LP, NCI...
    Trial ID:
    NCT05588141
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    PRNewswire
    Title:

    Adastra Pharmaceuticals Announces Positive Top-Line Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent High-grade Gliomas

    Published date:
    01/13/2021
    Excerpt:
    The trial investigated the safety and efficacy of ZTR, in combination with temozolomide (TMZ), in patients with recurrent high-grade gliomas....In the subset of patients who had isocitrate dehydrogenase (IDH) mutated tumors, the combined treatment with ZTR and temozolomide conferred a profound benefit of mPFS over historical control.
    Secondary therapy:
    temozolomide